DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Fallopian Tube Serous Adenocarcinoma — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFallopian Tube Serous Adenocarcinoma maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fallopian tube serous adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
mechanistic target of rapamycin kinase (MTOR) — MTOR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ihpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9T94 · 2.6 Å · ligand INOSITOL HEXAKISPHOSPHATE (IHP). Experimental structure, not a prediction.
What the evidence adds up to
Primary adenocarcinoma of the fallopian tube is rare, making up about 0.5% of female genital tract malignancies. A 1978 review of roughly 900 reported cases plus 10 new ones noted that four of the new patients survived more than three years, but the prognosis was generally poor. A 2021 retrospective study of 17 patients treated between 1991 and 2005 at a Tunisian institute found a median follow-up of 24 months; 11 of the 17 died of disease. The 5-year overall survival was 21% and the 5-year disease-free survival was 37%. Only the presence of residual tumour after surgery was a significant predictor of survival. Optimal cytoreductive surgery with no residual tumour was the main goal.
A 2013 study from Thailand examined 30 patients with primary fallopian tube cancer who received adjuvant paclitaxel and carboplatin chemotherapy. The 5-year progression-free survival for the whole group was 37.2%, with a median progression-free survival of 26.0 months. For stage I disease the 5-year progression-free survival was 75.0%, for stage II it was 51.4%, and for stage III it was 18.5%. Serous histology and stage were significant independent predictors of progression-free survival, with adjusted hazard ratios of 7.54 and 6.19 respectively. A 2010 case report of a patient with primary metastatic leiomyosarcoma of the fallopian tube (a different histology) described treatment with gemcitabine 900 mg/m² and docetaxel 100 mg/m²; after two cycles the disease progressed and the patient died within eight months of diagnosis.
The evidence for fallopian tube serous adenocarcinoma comes from small retrospective series, not from prospective trials. The 2021 study had only 17 patients, the 2013 study had 30. No randomised controlled trials exist for this specific disease. What is missing is any prospective trial design, adequate funding to recruit sufficient patients across multiple centres, and a method to stratify patients by molecular subtype rather than just stage and histology.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Australian and New Zealand Journal of Obstetrics and Gynaecology · 1978 · 20 citations
Primary Adenocarcinoma of the Fallopian Tube
AbstractSummary: Primary adenocarcinoma of the Fallopian tube is a rare lesion with a generally poor prognosis; it has an incidence of approximately 0.5% of all female genital tract malignancies. To date, approximately 900 cases have been described in the literature; the present paper adds another 10 cases and compares the pathology, clinical data, and outcome with the findings of other authors. Four patients survived more than 3 years.
Oncology Research and Treatment · 2010 · 8 citations
Primary Metastatic Leiomyosarcoma of the Fallopian Tube: A Rare Case Report
AbstractBACKGROUND: Leiomyosarcoma of the fallopian tube is an extremely unusual gynecologic neoplasm. Since 1886, only 19 of about 35 sarcomas of the fallopian tube have been identified as leiomyosarcomas. As such, clinical diagnosis and therapy management are difficult. CASE REPORT: We report on the case of a 59-year-old woman with leiomyosarcoma of the fallopian tube and liver metastases at the time of diagnosis. After initial tumor debulking, she received palliative chemotherapy with gemcitabine 900 mg/m(2) (d1+8) and docetaxel 100 mg/m(2) (d8) (q21). For additional bone metastases, she started local radiation plus bisphosphonates (q28). After 2 cycles of chemotherapy, the disease progressed, and the patient died within 8 months of diagnosis. A review of the literature is given. CONCLUSIONS: Primary metastatic leiomyosarcoma of the fallopian tube is a progressive disease with limited therapy options. For better prognostic evaluation and disease management in such rare cases, it is important to report and compare more cases regarding course of disease and outcome.
Gynecology Obstetrics and Reproductive Medicine · 2021 · 4 citations · open access
Primary Fallopian Tube Carcinoma: Results of a Single-Institutional Retrospective Analysis of 17 Patients with Evaluation of Staging and Prognostic Factors
AbstractOBJECTIVE: Primary carcinoma of the fallopian tubes is one of the less common gynecological cancers. It constitutes (0.14-0.18%) of gynecological malignancies. Our study aimed to review the managing process of primary carcinoma of the fallopian tubes in the mono-center institute and to identify prognostic factors impacting survival. STUDY DESIGN: A retrospective cohort study regarding patients with fallopian tube carcinoma treated between July 1991 and December 2005 was identified at the Tunisian anticancer institute “Salah Azaiez”. During this period, we have identified 17 patients. Data such as age, gravidity and parity, menopausal condition, symptoms reported by the patient on presentation, adjuvant therapy, stage of illness, surgical intervention, pathological findings, tumor recurrence, and previous surgical procedures were obtained from the patients’ reports. RESULTS: The average age at the time of diagnosis was 58 years. Fourteen of the included patients were postmenopausal. Surgery was the initial therapy for 15 patients. Optimal cytoreductive surgery was achievable in seven patients with no residual tumors. Histologic examination revealed that serous adenocarcinoma type was the predominant type. Two were in stage I and, four were in stage II; seven were in stage III and four in stage IV. The median follow-up time was 24 months. At the time of the final analysis, 11 patients died of disease. 5-year OS, DFS was 21% and 37% respectively. In our study, only the residual tumor was a significant prognostic factor predicting survival. CONCLUSION: Complete optimal surgery with no residual tumor was the main goal of the surgeon to improved survival in primary fallopian tube carcinoma.
Journal of obstetrics and gynaecology research · 2013 · 4 citations
Survival and prognostic factors of patients with primary fallopian tube cancer receiving adjuvant paclitaxel and carboplatin chemotherapy
AbstractAIM: To determine the survival and prognostic factors of patients with primary fallopian tube cancer (PFTC) who had been treated with paclitaxel and carboplatin chemotherapy. METHODS: The records of patients with PFTC who had been treated between 2002 and 2010, identified through the report of Chiang Mai University Hospital, were reviewed. All patients had pathological materials initially reported or reviewed by a gynecologic pathologist before initiation of treatment. RESULTS: Thirty patients met the inclusion criteria. Median age was 51 years. Serous adenocarcinoma was observed in the majority of patients (76.7%). Approximately 46% of patients were in stage I–II. The 5-year progression-free survival (PFS) for all patients was 37.2%. The 5-year PFS was 75.0% for stage I, 51.4% for stage II and 18.5% for stage III. Median PFS of the entire cohort was 26.0 months with a 95% confidence interval (CI) of 18.7–33.3 months. This rate was 18.5 months (95% CI, 6.7–35.6) for stage III whereas it was not reached for patients of stage I–II. Serous histology and stage were noted to be significant independent predictors of PFS with an adjusted hazards ratio of 7.54 (95% CI, 1.34–42.4) and 6.19 (95% CI, 1.59–24.08), respectively. CONCLUSION: The 5-year PFS of the whole cohort was 37.2% with a median survival of 26 months. International Federation of Gynecology and Obstetrics stage and histological subtype were a significant independent factor for predicting PFS.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
